Clinicians’ Evaluation of Lung Cancer Clinical Quality Indicators and Comparative Performance Data in Practice
Table 1
EnRICH quality indicators.
Diagnosis
(1). Proportion of patients diagnosed ≤28 days of the first investigation of symptoms suspicious of lung cancer (earliest of clinical or pathological diagnosis)
(2). Proportion of patients with a pathological diagnosis ≤28 days of the first investigation of symptoms suspicious of lung cancer
(3). Proportion of NSCLC patients with molecular testing (stage IV only, excl. squamous cell)
(4). Proportion of stage III patients reviewed by an MDT prior to curative treatment
Treatment
(5). Proportion of stage I–III patients with curative treatment ≤28 days of diagnosis
(6). Proportion of stage IV patients, initiating systemic treatment ≤28 days of diagnosis
(7). Proportion of stage I–III patients initiating curative treatment ≤ 28 days of site presentation
(8). Proportion of stage IV patients initiating systemic treatment ≤ 28 days of site presentation
Quality of life
(9). Proportion of stage IV NSCLC referred to palliative care ≤8 weeks of diagnosis
